1. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro
- Author
-
Jin Sun, Xuewen Yang, Huijing Mai, Zu-Bing Li, Yuehai Yu, and Yan Xu
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Necrosis ,Pamidronate ,Mandible ,03 medical and health sciences ,0302 clinical medicine ,Osteogenesis ,immune system diseases ,Internal medicine ,medicine ,Humans ,Wnt Signaling Pathway ,Cells, Cultured ,Diphosphonates ,Activator (genetics) ,business.industry ,Mesenchymal stem cell ,Osteonecrosis ,Wnt signaling pathway ,Mesenchymal Stem Cells ,respiratory system ,In vitro ,respiratory tract diseases ,Blot ,030104 developmental biology ,Endocrinology ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Cancer research ,Alkaline phosphatase ,Surgery ,Oral Surgery ,medicine.symptom ,business ,WNT3A - Abstract
Pamidronate disodium-associated bone necrosis is poorly understood at the cellular and molecular levels. This study proposes a pathway leading to the pamidronate disodium-mediated inhibition of osteogenic differentiation of human bone marrow mesenchymal stem cells (BMMSCs) derived from the mandible in vitro.Primary human BMMSCs were isolated from the mandible and marrow tissue. A proliferation assay was performed to determine the experimental concentration of pamidronate disodium. Alkaline phosphatase (ALP) activity, ALP staining, and Alizarin red S (ARS) staining were assessed after treatment with pamidronate disodium (0, 0.1, 0.5, 1, 5, 10 μg/mL). Quantitative real-time polymerase chain reaction and western blotting specific for Wnt and β-catenin signaling genes or proteins were performed after treatment with pamidronate disodium 0.5 μg/mL. Wnt3a was used to observe the osteogenic differentiation of BMMSCs during treatment with pamidronate disodium 0.5 μg/mL.As expected, pamidronate disodium 1, 5, and 10 μg/ml were unfavorable for BMMSC growth (P .05), whereas 0.1 and 0.5 μg/mL did not affect BMMSC growth (P ≥ .05). BMMSCs treated with pamidronate disodium 0.5 μg/mL had lower ALP activity, ALP staining, and ARS staining (P .05), and BMMSCs treated with low concentrations (0.5 μg/mL) of pamidronate disodium had the same levels of ALP activity, ALP staining, and ARS staining as the control (0 μg/mL). Pamidronate disodium 0.5 μg/mL decreased the expression of genes and proteins involved in Wnt and β-catenin signaling. BMMSCs with Wnt3a and pamidronate disodium 0.5 μg/mL had higher ALP activity, ALP staining, and ARS staining (P .05).Pamidronate disodium inhibited Wnt and β-catenin signaling, which controls osteogenic differentiation in BMMSCs. Wnt3a, a Wnt and β-catenin signaling activator, reversed the negative effects caused by pamidronate disodium to salvage the osteogenic defect in BMMSCs.
- Published
- 2017
- Full Text
- View/download PDF